Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.
Patients with early bladder cancer who have gone 5 years without relapse may be considered “cured,” researchers suggested. In considering outcomes for evaluating how “cure” is defined in early bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results